Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-936557 (Anti-IP-10 Antibody)
BMS-936557 · 1 trial · 1 indication
CDAI: Crohn's Disease Activity Index
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Induction | EXPERIMENTAL | Placebo |
| Cohort 2: Induction | EXPERIMENTAL | Anti-IP-10 Antibody |
| Cohort 3: Induction | EXPERIMENTAL | Anti-IP-10 Antibody |
| Cohort 1: Maintenance | EXPERIMENTAL | Placebo |
| Cohort 2: Maintenance | EXPERIMENTAL | Anti-IP-10 Antibody |
| Cohort 3: Maintenance | EXPERIMENTAL | Anti-IP-10 Antibody |
| Cohort 1: Open Label | EXPERIMENTAL | Anti-IP-10 Antibody |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks |
| BMS-936557 (Anti-IP-10 Antibody) | DRUG | Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks |
Inclusion Criteria: * Adults subjects with confirmed Crohn's Disease (CD) for at least 3 months * Moderate to severely active CD as defined by Crohn's Disease Activity Index (CDAI) 220 to 450 * In the past have had insufficient response and or intolerance to ≥ 1 of the conventional therapy (immunos...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Duvakitug, balinatunfib, Brivekimig |
| AbbVie, Inc. | ABBV | 16 | PHASE3 | Upadacitinib, Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736 |
| Eli Lilly and Company | LLY | 7 | PHASE3 | Mirikizumab, Tirzepatide, LY4395089, MORF-057 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 15 | PHASE3 | Vedolizumab, Zasocitinib, Darvadstrocel |
| Johnson & Johnson | JNJ | 24 | PHASE3 | Ustekinumab, Guselkumab, JNJ-78934804, Golimumab, Icotrokinra |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Spyre Therapeutics, Inc | SYRE | 2 | PHASE2 | SPY001, SPY002, SPY003 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Shattuck Labs, Inc. | STTK | 1 | PHASE2 | SL-325 |
| AgomAb Therapeutics NV ADR | AGMB | 2 | PHASE2 | Ontunisertib |
| Hoffmann-La Roche | RHHBY | 1 | PHASE2 | Afimkibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Etrasimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
BMS-936557 is an investigational therapy that was studied for the treatment of moderate to severely active Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract. It was evaluated in a Phase 2 clinical trial in adults with this condition. It is not approved for any indication.
BMS-936557 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company sponsored the clinical research program for this asset in Crohn's disease.
BMS-936557 is in Phase 2 development. It has completed one Phase 2 clinical trial in patients with moderate to severely active Crohn's disease. The trial has been completed and there are no active trials of this drug currently listed.
BMS-936557 was evaluated in a single Phase 2 trial, NCT01466374, titled Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease. The trial enrolled 121 patients across the United States, Belgium, France, Hungary, Israel, Poland, Puerto Rico, and South Africa, and it is now completed.
Yes, BMS-936557 is also known as BMS-936557 (Anti-IP-10 Antibody). The parenthetical name reflects its classification as an antibody directed against IP-10. Both names refer to the same investigational compound studied in Crohn's disease.